Zilovertamab Vedotin Unveils Promising Clinical Activity in Relapsed/Refractory DLBCL

Zilovertamab vedotin Phase II Results

Zilovertamab vedotin is an experimental antibody-drug conjugate that specifically targets receptor tyrosine kinase-like orphan receptor 1 (ROR1), which is a transmembrane protein that exhibits heightened expression in various hematologic malignancies.

According to the findings presented at the ASCO 2023 conference, early Phase II results indicate that zilovertamab vedotin exhibits potential in terms of its ability to combat tumor growth. The study has enrolled a total of 40 patients, and recruitment of patients is still ongoing. Within this group, 40% of patients had previously undergone two lines of therapy, while 28% had received chimeric antigen receptor (CAR) T-cell therapy. The data cutoff point was set at a median time of 2.6 months from the initial dosage. As of the cutoff, 17 patients were still undergoing treatment.

The analysis of the data revealed an overall response rate of 30% and a disease control rate of 55%. Out of the total patients, two achieved a complete response, four had a partial response, and five experienced stable disease.

Efficacy Outcomes

Zilovertamab Vedotin


Overall response rate


Disease control rate


A total of 70% of patients experienced adverse events of any grade, with 40% of patients experiencing grade 3-4 events, according to the study. Notably, one patient discontinued treatment due to diabetic ketoacidosis.

KOL insights

“Early results show that zilovertamab vedotin had clinically meaningful antitumor activity in patients with relapsed/refractory DLBCL. Additionally, the safety profile was manageable and consistent with other monomethyl auristatin E-containing agents.” –Expert Opinion.


Exciting early findings from the waveLINE-004 study have demonstrated the significant antitumor activity of zilovertamab vedotin in patients diagnosed with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) who have either experienced disease progression after or were ineligible for autologous stem cell transplantation (ASCT) and/or chimeric antigen receptor T-cell (CAR-T) therapy. Moreover, the safety profile of zilovertamab vedotin has proven to be manageable and consistent with other agents containing monomethyl auristatin E (MMAE). These compelling results provide strong support for the ongoing investigation and exploration of zilovertamab vedotin as a potential treatment option for patients with R/R DLBCL.